Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont.  

In the phase 2b clinical study of DBI-001 in tinea pedis, once-daily application of the agent for 28 days resulted in statistically significant decreases in the abundance in T. rubrum, statistically significant improvement in the signs and symptoms of tinea pedis, statistically significant improvement in the investigator static global assessment, beneficial changes in the microbial community, and no safety or tolerability issues.

The phase 2a trial in atopic dermatitis was primarily designed as a safety and tolerability study with a secondary endpoint to demonstrate that DBI-001 could have a favorable effect on the skin microbiome of atopic dermatitis patients. A single topical application of investigational drug product showed DBI-001 to be well tolerated with no safety issues while also resulting in decreased abundance of S. aureus as well as changes in the community of microorganisms on patients’ skin.

“DermBiont was founded to lead the field of evidence-based dermatology therapeutics that treat diseases at their root cause,” says Nichola Eliovits, a co-founder and CBO. “Our unique and industry leading position within the field of the skin microbiome continues to advance with the success of this program and the expansion of our understanding of the microbiome.Importantly, this trial has also provided DermBiont with a number of unexpected discoveries that extend beyond our public disclosures and provide us with a number of competitive advantages across our entire biotherapeutics pipeline.”